Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans
This cross-sectional study examines trends in coverage of glucagon-like peptide-1 receptor agonists, semaglutide and tirzepatide, and prior authorization requirements among Medicare Part D beneficiaries.
Authors
- Changchuan Jiang (ORCID: https://orcid.org/0000-0002-7392-4154)
- Ya‐Chen Tina Shih (ORCID: https://orcid.org/0000-0001-7290-3864)
- Changzheng Lu (ORCID: https://orcid.org/0000-0002-0904-0303)
- Xiaoyu Liu (ORCID: https://orcid.org/0009-0001-8033-1517)
Institutions
- University of California, Los Angeles (US)
- UCLA Health (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.29842
- Citations
- 5
- Primary Topic
- Medication Adherence and Compliance
- Type
- article
- Field-Weighted Citation Impact
- 7.58
Funders
- Sanofi
- National Cancer Institute